Defining Ubiquitin Ligase Substrates: New Therapeutic Strategies In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$598,163.00
Summary
Current cancer therapies use drugs that target both tumor cells and rapidly growing normal cells – causing side effects and limiting effectiveness. Newer treatments aim to target molecules that are unique to tumor cells, leaving normal cells unharmed. This project will study a process that tags proteins for destruction by a cellular recycling system, which is often disrupted in cancer. This research will not only help us understand how cancer develops, but also identify new targets for therapy.
Identification Of PACE-1 As A Novel Therapeutic Target For The Treatment Of Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$606,144.00
Summary
Advanced prostate cancer (PCa) remains the major therapeutic challenge since neither surgery nor systemic therapies are effective at this stage. Recently, we identified a protein called PACE-1 that is essential for PCa cell survival. We plan to investigate the roles of PACE-1 in the development and progression of prostate cancer. We will then test if PACE-1 inactivation alone or in combination with systemic cancer therapies will inhibit prostate tumor growth and disease progression.
A Novel Approach To Restoration Of Tumour Suppression In Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$598,604.00
Summary
Loss of a tumour suppressor is a key event in every cancer, including lung cancer. Therefore restoration of the expression and/or activity of the tumour suppressor is an attractive approach to anti-cancer treatment. In order to restore tumour suppression, a detailed understanding of the mechanism by which a given tumour suppressor is regulated is required. This application focuses on our discovery of a novel mechanism by which a key tumour suppressor of lung cancer is regulated.
Functional Characterisation Of A New Surface Adhesion Molecule On Human Vascular Progenitor Cells To Combat Cancer
Funder
National Health and Medical Research Council
Funding Amount
$593,794.00
Summary
Collectively, diseases of the blood vascular system contribute immensely to the burden of health care in Australia. Notably, abnormal blood vessel formation is a major cause or contributor to many diseases, such as cancer, cardiovascular disease, rheumatoid arthritis, ischemia injury and diabetes. This project aims to understand the underlying mechanisms associated with aberrant angiogenesis such that it may aid in the identification of novel targets for the development of therapeutics.
A Novel Approach For Treating B-cell Lymphoma By Inhibition Of The E3 Ligase E6AP
Funder
National Health and Medical Research Council
Funding Amount
$624,846.00
Summary
B-cell lymphoma is the most common type blood cancer diagnosed in Australia, and Australia's fifth most common cancer. Despite remarkable advances in diagnosis and treatment, lymphoma continues to rank as a leading cause of cancer-related mortality. Our pilot studies reveal a novel approach to treatment of B-cell lymphoma by inhibiting an enzyme that destroys our natural mechanism of defense against cancer. In this study we will test the efficacy of this novel treatment.